Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 12/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11788559 | 0.79 | TSHR (0.42) | CYP1A2GAAMAPTKMT2A | |
| SCHEMBL13748726 | 0.71 | IDH1 (0.44) | SMN1; SMN2CYP1A2IDH1 | |
| SCHEMBL23264408 | 0.71 | IDO1 (0.47) | GSK3BKDM4EGAAMAPT | |
| SCHEMBL19696036 | 0.71 | IDO1 (0.47) | GSK3BKDM4EGAAMAPT | |
| SCHEMBL30839791 | 0.71 | IDO1 (0.47) | GSK3BKDM4EGAAMAPT | |
| SCHEMBL2764856 | 0.71 | IDO1 (0.47) | GSK3BKDM4EGAAMAPT | |
| SCHEMBL7476995 | 0.70 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP1A2GSK3BKDM4EGAA | |
| SCHEMBL7102226 | 0.70 | — | — | |
| SCHEMBL21685918 | 0.68 | TNKS2 (0.35) | GSK3B | |
| SCHEMBL28128051 | 0.68 | GSK3B (0.48) | SMN1; SMN2CYP1A2IDH1GSK3BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3250035-B1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS INC (TW) | 2023-01-25 | — | — | EP | disclosed |
| US-10870635-B2 | Compounds and their use as BACE1 inhibitors | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2020-12-22 | — | — | US | disclosed |
| US-20180201604-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2018-07-19 | — | — | US | disclosed |
| EP-3250035-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | Allgenesis Biotherapeutics Inc. (TW) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016172255-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10870635-B2 | Compounds and their use as BACE1 inhibitors | BACE1, BACE2, APP | SMN1; SMN2 56/4885CYP1A2 3610/4885IDH1 4123/4885 |
| US-20180201604-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | BACE1, BACE2, APP | SMN1; SMN2 55/4885CYP1A2 3624/4885IDH1 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.